METHOD FOR PREDICTING THE DEVELOPMENT OF LIFE-THREATENING VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH IN PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE WITH A REDUCED EJECTION FRACTION WITHIN 12 MONTHS AFTER IMPLANTATION OF A CARDIOVERTER DEFIBRILLATOR

摘要

FIELD: medicine. ;SUBSTANCE: invention relates to medicine and can be used in cardiology, angiology, cardiac surgery, therapy, rehabilitation. Before the implantation of a cardioverter defibrillator, galectin-3 in the blood serum is determined in the patient by an enzyme immunoassay. With a galectin-3 level of 16.6 ng/ml or more, patients with coronary heart disease and heart failure with a reduced left ventricular ejection fraction are predicted to have a high risk of developing life-threatening ventricular arrhythmias and sudden cardiac death during the next 12 months of follow-up after implantation of a cardioverter defibrillator. The method makes it possible to predict a life-threatening risk by determining a fibrosis marker in the blood serum, galein-3, which makes it possible to identify a priority group of patients with an increased risk of cardiovascular complications for dispensary observation with the organization of effective targeted measures aimed at preventing ventricular arrhythmias and sudden cardiac death. ;EFFECT: method makes it possible to predict a high risk of life-threatening ventricular arrhythmias and sudden cardiac death caused by excessive fibroblast proliferation, collagen deposition and cardiac remodeling during 12 months of follow-up after implantation of a cardioverter defibrillator.;1 cl, 1 dwg, 1 tbl, 2 ex